Quader Sabina, Van Guyse Joachim F R
Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 212-0821, Japan.
Leiden Academic Center for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands.
Polymers (Basel). 2022 Sep 3;14(17):3659. doi: 10.3390/polym14173659.
Bioresponsive polymers in nanomedicine have been widely perceived to selectively activate the therapeutic function of nanomedicine at diseased or pathological sites, while sparing their healthy counterparts. This idea can be described as an advanced version of Paul Ehrlich's magic bullet concept. From that perspective, the inherent anomalies or malfunction of the pathological sites are generally targeted to allow the selective activation or sensory function of nanomedicine. Nonetheless, while the primary goals and expectations in developing bioresponsive polymers are to elicit exclusive selectivity of therapeutic action at diseased sites, this remains difficult to achieve in practice. Numerous research efforts have been undertaken, and are ongoing, to tackle this fine-tuning. This review provides a brief introduction to key stimuli with biological relevance commonly featured in the design of bioresponsive polymers, which serves as a platform for critical discussion, and identifies the gap between expectations and current reality.
纳米医学中的生物响应性聚合物已被广泛认为能够在患病或病理部位选择性地激活纳米医学的治疗功能，同时使健康部位免受影响。这一理念可被描述为保罗·埃尔利希的魔弹概念的升级版。从这个角度来看，病理部位的固有异常或功能失调通常是纳米医学选择性激活或传感功能的靶向目标。尽管如此，虽然开发生物响应性聚合物的主要目标和期望是在患病部位实现治疗作用的专属选择性，但在实践中这仍然难以实现。为了解决这种微调问题，已经开展了许多研究工作，并且仍在进行中。本综述简要介绍了生物响应性聚合物设计中常见的具有生物学相关性的关键刺激因素，作为关键讨论的平台，并指出了期望与当前现实之间的差距。
